New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.69 2.16 +1.30%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. (GILD) EPS (diluted)

Alert me on EPS (diluted)

Gilead Sciences, Inc.'s EPS (diluted) for fiscal 2025 was $6.78, up 1,684.2% from $0.38 in fiscal 2024. Over the twelve months to Sep 30, 2026 it was −$3.16. Over the past ten years it has ranged from $0.10 (fiscal 2020) to $11.91 (fiscal 2015); the current reading is higher than 82% of that period. Gilead Sciences, Inc. ranks 18th of 20 Drug Manufacturers General companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 $6.78 1,684.21%
FY2024 $0.38 (91.56%)
FY2023 $4.50 23.63%
FY2022 $3.64 (26.17%)
FY2021 $4.93 4,830.00%
FY2020 $0.10 (97.63%)
FY2019 $4.22 1.20%
FY2018 $4.17 18.80%
FY2017 $3.51 (64.69%)
FY2016 $9.94 (16.54%)

Quarterly newest first

Period EPS (diluted) Change
Sep 2026 $1.94 —
Jun 2026 −$8.45 —
Mar 2026 $1.61 (7.47%)
Dec 2025 $1.74 (28.40%)
43 more quarters

Against its own ten years

Low $0.10 High $11.91
Ten-year median $4.22
Current reading's percentile 82

EPS (diluted) against peers

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on GILD